Evidence map›Paper›PMID 31771274›Full record

ArticleNanomaterials (Basel, Switzerland)2019

Micronuclei Detection by Flow Cytometry as a High-Throughput Approach for the Genotoxicity Testing of Nanomaterials.

Alba García-Rodríguez, Liliya Kazantseva, Laura Vila, Laura Rubio, Antonia Velázquez, María José Ramírez, Ricard Marcos, Alba Hernández

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Flow Cytometric Determination of Micronucleus Frequency.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Genotoxicity of nanoparticles evaluated using theJournal of environmental science and health. Part C, Toxicology and carcinogenesis · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alba García-RodríguezDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Liliya KazantsevaDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Laura VilaDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Laura RubioDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Antonia VelázquezDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
María José RamírezConsortium for Biomedical Research on Rare Diseases (CIBERER), Carlos III Institute of Health, 28029 Madrid, Spain.
Ricard MarcosDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Alba HernándezDepartment of Genetics and Microbiology, Faculty of Biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

Funding

Ministerio de Ciencia, Innovación y Universidades SAF2015-63519-RSeventh Framework Programme NMP4-LA-2013-310584
6 · The paper itself

Abstract

Thousands of nanomaterials (NMs)-containing products are currently under development or incorporated in the consumer market, despite our very limited understanding of their genotoxic potential. Taking into account that the toxicity and genotoxicity of NMs strongly depend on their physicochemical characteristics, many variables must be considered in the safety evaluation of each given NM. In this scenario, the challenge is to establish high-throughput methodologies able to generate rapid and robust genotoxicity data that can be used to critically assess and/or predict the biological effects associated with those NMs being under development or already present in the market. In this study, we have evaluated the advantages of using a flow cytometry-based approach testing micronucleus (MNs) induction (FCMN assay). In the frame of the EU NANoREG project, we have tested six different NMs-namely NM100 and NM101 (TiO

Indexed as

AgNPsBEAS-2B cellsCeO2NPsflow cytometry MN (FCMN) assayMWCNTsTiO2NPsZnONPs

Identifiers

PMID31771274
PMCPMC6956333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.